Journal
ANNALES D ENDOCRINOLOGIE
Volume 79, Issue 5, Pages 591-595Publisher
MASSON EDITEUR
DOI: 10.1016/j.ando.2018.07.005
Keywords
Immunotherapy; Tyrosine kinase inhibitors; MTOR inhibitors; Dysthyroidism; Hypophysitis; Diabetes; Dyslipidemia; Adrenal failure
Categories
Ask authors/readers for more resources
The present final consensus statement of the French Society of Endocrinology lays out the assessments that are to be systematically performed before and during anticancer treatment by immunotherapy, tyrosine kinase inhibitors or mTOR inhibitors, even without onset of any endocrinopathy. It also discusses the CTCAE adverse event grading system in oncology and the difficulty of implementing it for endocrine side-effects of these anticancer treatments. Notably, this is why certain treatment steps applied in other side-effects (e.g., high-dose corticosteroids, contraindications to immunotherapy, etc.) need to be discussed before implementation for endocrine side-effects. (C) 2018 Elsevier Masson SAS. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available